vs

Side-by-side financial comparison of DARLING INGREDIENTS INC. (DAR) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

DARLING INGREDIENTS INC. is the larger business by last-quarter revenue ($1.6B vs $961.0M, roughly 1.6× DENTSPLY SIRONA Inc.). DARLING INGREDIENTS INC. runs the higher net margin — 1.2% vs -15.2%, a 16.4% gap on every dollar of revenue. On growth, DARLING INGREDIENTS INC. posted the faster year-over-year revenue change (10.0% vs 6.2%). Over the past eight quarters, DENTSPLY SIRONA Inc.'s revenue compounded faster (0.4% CAGR vs -1.6%).

Darling Ingredients Inc. is a global sustainable natural ingredients maker that converts edible and inedible organic byproducts into high-value products: food-grade nutritional ingredients, animal feed additives, pharmaceutical raw materials and biofuel components, serving food, agriculture, pharma and renewable energy markets across North America, Europe and Asia-Pacific.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

DAR vs XRAY — Head-to-Head

Bigger by revenue
DAR
DAR
1.6× larger
DAR
$1.6B
$961.0M
XRAY
Growing faster (revenue YoY)
DAR
DAR
+3.8% gap
DAR
10.0%
6.2%
XRAY
Higher net margin
DAR
DAR
16.4% more per $
DAR
1.2%
-15.2%
XRAY
Faster 2-yr revenue CAGR
XRAY
XRAY
Annualised
XRAY
0.4%
-1.6%
DAR

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
DAR
DAR
XRAY
XRAY
Revenue
$1.6B
$961.0M
Net Profit
$19.4M
$-146.0M
Gross Margin
24.7%
46.1%
Operating Margin
4.6%
-14.5%
Net Margin
1.2%
-15.2%
Revenue YoY
10.0%
6.2%
Net Profit YoY
14.2%
66.0%
EPS (diluted)
$0.12
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DAR
DAR
XRAY
XRAY
Q4 25
$961.0M
Q3 25
$1.6B
$904.0M
Q2 25
$1.5B
$936.0M
Q1 25
$1.4B
$879.0M
Q4 24
$1.4B
$905.0M
Q3 24
$1.4B
$951.0M
Q2 24
$1.5B
$984.0M
Q1 24
$1.4B
$953.0M
Net Profit
DAR
DAR
XRAY
XRAY
Q4 25
$-146.0M
Q3 25
$19.4M
$-427.0M
Q2 25
$12.7M
$-45.0M
Q1 25
$-26.2M
$20.0M
Q4 24
$101.9M
$-430.0M
Q3 24
$16.9M
$-494.0M
Q2 24
$78.9M
$-4.0M
Q1 24
$81.2M
$18.0M
Gross Margin
DAR
DAR
XRAY
XRAY
Q4 25
46.1%
Q3 25
24.7%
48.8%
Q2 25
23.3%
52.4%
Q1 25
22.6%
53.0%
Q4 24
23.5%
49.3%
Q3 24
22.1%
52.1%
Q2 24
22.5%
51.9%
Q1 24
21.4%
53.1%
Operating Margin
DAR
DAR
XRAY
XRAY
Q4 25
-14.5%
Q3 25
4.6%
-24.1%
Q2 25
5.1%
-13.7%
Q1 25
2.1%
7.2%
Q4 24
8.6%
-56.2%
Q3 24
4.2%
-48.6%
Q2 24
10.2%
5.1%
Q1 24
9.7%
4.4%
Net Margin
DAR
DAR
XRAY
XRAY
Q4 25
-15.2%
Q3 25
1.2%
-47.2%
Q2 25
0.9%
-4.8%
Q1 25
-1.9%
2.3%
Q4 24
7.2%
-47.5%
Q3 24
1.2%
-51.9%
Q2 24
5.4%
-0.4%
Q1 24
5.7%
1.9%
EPS (diluted)
DAR
DAR
XRAY
XRAY
Q4 25
$-0.74
Q3 25
$0.12
$-2.14
Q2 25
$0.08
$-0.22
Q1 25
$-0.16
$0.10
Q4 24
$0.63
$-2.09
Q3 24
$0.11
$-2.46
Q2 24
$0.49
$-0.02
Q1 24
$0.50
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DAR
DAR
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$91.5M
$326.0M
Total DebtLower is stronger
$4.0B
$2.3B
Stockholders' EquityBook value
$4.7B
$1.3B
Total Assets
$10.5B
$5.4B
Debt / EquityLower = less leverage
0.86×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DAR
DAR
XRAY
XRAY
Q4 25
$326.0M
Q3 25
$91.5M
$363.0M
Q2 25
$94.6M
$359.0M
Q1 25
$81.5M
$398.0M
Q4 24
$76.0M
$272.0M
Q3 24
$114.8M
$296.0M
Q2 24
$121.6M
$279.0M
Q1 24
$145.5M
$291.0M
Total Debt
DAR
DAR
XRAY
XRAY
Q4 25
$2.3B
Q3 25
$4.0B
Q2 25
$3.9B
Q1 25
$3.8B
Q4 24
$3.9B
$1.7B
Q3 24
$4.1B
Q2 24
$4.3B
Q1 24
$4.4B
Stockholders' Equity
DAR
DAR
XRAY
XRAY
Q4 25
$1.3B
Q3 25
$4.7B
$1.5B
Q2 25
$4.6B
$2.0B
Q1 25
$4.4B
$2.0B
Q4 24
$4.4B
$1.9B
Q3 24
$4.6B
$2.5B
Q2 24
$4.5B
$3.1B
Q1 24
$4.6B
$3.3B
Total Assets
DAR
DAR
XRAY
XRAY
Q4 25
$5.4B
Q3 25
$10.5B
$5.7B
Q2 25
$10.3B
$6.1B
Q1 25
$10.0B
$6.0B
Q4 24
$10.1B
$5.8B
Q3 24
$10.6B
$6.6B
Q2 24
$10.6B
$6.9B
Q1 24
$10.9B
$7.1B
Debt / Equity
DAR
DAR
XRAY
XRAY
Q4 25
1.70×
Q3 25
0.86×
Q2 25
0.85×
Q1 25
0.86×
Q4 24
0.89×
0.90×
Q3 24
0.91×
Q2 24
0.97×
Q1 24
0.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DAR
DAR
XRAY
XRAY
Operating Cash FlowLast quarter
$224.3M
$101.0M
Free Cash FlowOCF − Capex
$60.0M
FCF MarginFCF / Revenue
6.2%
Capex IntensityCapex / Revenue
4.3%
Cash ConversionOCF / Net Profit
11.59×
TTM Free Cash FlowTrailing 4 quarters
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DAR
DAR
XRAY
XRAY
Q4 25
$101.0M
Q3 25
$224.3M
$79.0M
Q2 25
$145.8M
$48.0M
Q1 25
$249.0M
$7.0M
Q4 24
$154.4M
$87.0M
Q3 24
$274.5M
$141.0M
Q2 24
$146.5M
$208.0M
Q1 24
$263.9M
$25.0M
Free Cash Flow
DAR
DAR
XRAY
XRAY
Q4 25
$60.0M
Q3 25
$40.0M
Q2 25
$16.0M
Q1 25
$-12.0M
Q4 24
$36.0M
Q3 24
$98.0M
Q2 24
$156.0M
Q1 24
$-9.0M
FCF Margin
DAR
DAR
XRAY
XRAY
Q4 25
6.2%
Q3 25
4.4%
Q2 25
1.7%
Q1 25
-1.4%
Q4 24
4.0%
Q3 24
10.3%
Q2 24
15.9%
Q1 24
-0.9%
Capex Intensity
DAR
DAR
XRAY
XRAY
Q4 25
4.3%
Q3 25
4.3%
Q2 25
3.4%
Q1 25
2.2%
Q4 24
5.6%
Q3 24
4.5%
Q2 24
5.3%
Q1 24
3.6%
Cash Conversion
DAR
DAR
XRAY
XRAY
Q4 25
Q3 25
11.59×
Q2 25
11.52×
Q1 25
0.35×
Q4 24
1.52×
Q3 24
16.19×
Q2 24
1.86×
Q1 24
3.25×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DAR
DAR

Fats$428.4M27%
Food Ingredients$380.6M24%
Diamond Green Diesel Holdings Llc Joint Venture$342.1M22%
Fuel Ingredients$154.3M10%
Used Cooking Oil$125.9M8%
Other Rendering$76.9M5%
Bakery$46.9M3%
Other Products And Services$12.2M1%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons